

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : C12N 5/06, 5/08, A61K 35/32 A61L 27/00, C12Q 1/18	A1	(11) International Publication Number: WO 93/19168 (43) International Publication Date: 30 September 1993 (30.09.93)
(21) International Application Number: PCT/CA93/00111 (22) International Filing Date: 18 March 1993 (18.03.93) (30) Priority data: 07/835,831 18 March 1992 (18.03.92) US (60) Parent Application or Grant (63) Related by Continuation US 07/835,831 (CIP) Filed on 18 March 1992 (18.03.92) (71) Applicant (for all designated States except US): MOUNT SINAI HOSPITAL CORPORATION [CA/CA]; 600 University Avenue, Toronto, Ontario M5G 1X5 (CA).	(72) Inventor; and (75) Inventor/Applicant (for US only): KANDEL, Rita, A. [CA/CA]; 430 Heath Street East, Toronto, Ontario M4G 1B5 (CA). (74) Agent: BERESKIN & PARR; 40 King Street West, 40th Floor, Toronto, Ontario M5H 3Y2 (CA). (81) Designated States: AU, CA, JP, RU, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published With international search report.	
(54) Title: RECONSTITUTED CARTILAGE TISSUE (57) Abstract The present invention relates to cartilage tissue reconstituted on a substrate; to a method for producing reconstituted cartilage tissue; and to cartilage tissue reconstituted in vitro from isolated chondrocytes cultured on a substrate.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LJ	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

Title: RECONSTITUTED CARTILAGE TISSUE

FIELD OF THE INVENTION

The present invention relates to reconstituted
5 cartilage tissue; to a method for producing reconstituted
cartilage tissue; and to cartilage tissue reconstituted in
vitro from isolated chondrocytes.

BACKGROUND OF THE INVENTION

Articular cartilage is a specialized tissue
10 found at the end of articulating bones. Cartilage, unlike
other connective tissues, lacks blood vessels, nerves,
lymphatics and basement membrane. It is responsible for
the distribution of load resistance to compressive forces,
and the smooth gliding that is part of joint function.

15 Cartilage is composed of chondrocytes which
synthesize an abundant extracellular matrix, which is
composed of water, collagens, proteoglycans and non-
collagenous proteins and lipids. Collagen serves to trap
proteoglycans and to provide tensile strength to the
20 tissue. Type II collagen is the predominant collagen in
cartilage tissue. The proteoglycans are composed of a
variable number of glycosaminoglycan chains, keratan
sulphate, chondroitin sulphate and/or dermatan sulphate,
and N-linked and O-linked oligosaccharides covalently
25 bound to a protein core. The sulphated glycosaminoglycans
are negatively charged resulting in an osmotic swelling
pressure that draws in water.

Although, histologically, articular cartilage
appears very homogenous, the matrix organization and
30 composition differ from the superficial to the deep zones
(Aydelotte and Kuettner, Conn. Tiss. Res. 18: 205, 1988;
Zanetti et al, J. Cell Biol. 101: 53, 1985; and Poole et
al, J. Anat. 138: 13, 1984). Articular cartilage appears
to be composed of zones which show a characteristic
35 gradation of features from the surface of the tissue to
the base of the tissue adjacent to the bone. In the
superficial zone, for example, chondrocytes are flattened

SUBSTITUTE SHEET

- 2 -

and lie parallel to the surface embedded in a matrix that contains tangentially arranged collagen and few proteoglycans. In the mid zone, chondrocytes are spherical and surrounded by a matrix rich in proteoglycans and obliquely organized collagen fibers. In the deep zone, close to the bone, the collagen fibers are vertically oriented. The keratan sulphate rich proteoglycans increase in concentration with increasing distance from the cartilage surface (Zanetti et al, supra).

Ultrastructural variation is evident between the pericellular and interterritorial matrix areas. The pericellular collagen fibers are much thinner and do not exhibit the usual 68 nm periodicity characteristic of collagen in the interterritorial zone. It is not known how these zones are established or maintained (Poole et al, supra; Urban and Bayliss, Biochem. Biophys. Acta. 992: 59, 1989; Brown et al, Conn. Tiss. Res. 24: 157, 1990; Schneiderman et al J. Orthop. Res. 4: 393, 1986).

Studies of cartilage organization and pathophysiology have been severely restricted by the limited availability of cartilage tissue and the inability of in vitro culture systems to mimic the organization of in vivo cartilage tissue. In vivo cartilage has been removed and maintained in explant cultures, but there are several problems associated with these cultures (Poole et al supra; Lane and Brighton, Arth. Rheum 17: 235, 1974; and Morales et al, J. Biol. Chem. 259: 6720, 1984). There is a loss of matrix molecules from the cartilage during culture, and the amount of cartilage available for experimentation is therefore limited. Chondrocytes have been isolated from cartilage and grown in monolayer culture systems (Manning and Bonner, Arth. Rheum. 10: 235, 1967; Horwitz and Dorfman, J. Cell Biol. 45: 434, 1970; and Green, Clin. Orthop. Rel. Res. 75: 248, 1971). However, chondrocyte phenotype in these cultures is labile and the chondrocytes dedifferentiate to fibroblasts, as defined by production of type I collagen and small non-

- 3 -

aggregating proteoglycans (Von der Mark et al, Nature 267: 531, 1977; and Solursh, Am. J. Med. Gen. 34: 30, 1989).

Maintaining chondrocytes in a spherical shape has been shown to slow down or prevent dedifferentiation of the chondrocyte phenotype (Watt and Dudhia, Differentiation 38: 140, 1988). Accordingly, culture systems have been developed to maintain the cells in a spherical shape. Primary cell cultures either plated at high density in monolayer or droplet form, in suspension culture, in collagen gel, in or on agarose gel, in composition agarose-collagen gels, in alginate or on apatite beads, or a combination of monolayer culture followed by transfer to agarose culture have been employed in an attempt to slow down or prevent dedifferentiation (Kuettner et al, J. Cell. Biol. 93: 743, 1982; Van Kampen and Veldhuijzen, Exp. Cell. Res. 140: 440, 1982; Delbruck et al, Conn. Tiss. Res. 15: 155, 1986; Thompson et al, Exp. Cell. Res. 157: 483, 1985; Bassler et al, In Vitro 22: 113, 1986; Cheung, In Vitro Cell. Dev. Biol. 21: 353, 1985; Guo et al, Conn. Tiss. Res. 19: 277, 1989; Aulthouse et al, In Vitro 25: 659, 1989; and Solursh, J. Cell. Biochem. 45: 258, 1991).

Alternative approaches to maintaining the chondrocyte phenotype have been to induce chondrogenesis by growing mesenchymal cells in diffusion chambers or in monolayer in the presence of beta TGF (O'Driscoll et al, Trans. Orthop. Res. 37: 125, 1991 and Nakahara et al, Bone 11: 181, 1990), or perichondrial grafts (Amiel et al, Conn. Tiss. Res. 18: 27, 1988). Under all of the above conditions the chondrocytes maintain at least a partial chondrocyte phenotype, as indicated by the synthesis of type II collagen and proteoglycans specific to articular cartilage. However, there are a number of problems with these types of cultures. Proliferation in some of the cultures is inhibited so that only a limited number of cells can be generated. It has also proved difficult to isolate cells from these cultures. The most important limitation, however, is that none of these culture systems

- 4 -

can mimic the in vivo morphology of articular cartilage, including the cellular and matrix organization described above.

- Green (Clin. Orth. Rel. Res. 75:248, 1971)
- 5 teaches a process for growing chondrocytes in vitro in pelleted aggregate cultures on Millipore cellulose acetate inserts. Green describes the in vitro production of a chondro-myxoid matrix by rabbit chondrocytes. Kuettner et al (J. Cell. Biol. 93:751, (1982)) describe methods of
- 10 culturing bovine chondrocytes on plastic dishes. Kuettner in U.S. Patent No. 4,356,261 describes methods of culturing chondrocytes in suspension culture in roller bottles. Type II collagen was reported as being the major matrix-associated collagen synthesized in vitro. Kuettner
- 15 et al analyzed proteoglycans synthesized by the chondrocytes in their culture system by chromatography of ³⁵S pulse-labelled cultures. The proteoglycans synthesized were compared with those of in vivo bovine articular cartilage. Bassler et al (1986) teach a suspension
- 20 culture of human chondrocytes wherein aggregates of chondrocytes with secreted matrix were produced by a gyratory shaker. Type II collagen and proteoglycans were detected in the secreted matrix by immunofluorescence and radioimmunoassay.
- 25 Cheung (In Vitro Cell. Dev. Biol. 21:353, 1985) teaches a method of culturing canine chondrocytes on porous hydroxyapatite ceramic granules. The cells reportedly proliferated and secreted metachromatic extracellular matrix for up to 13 months. An agarose gel
- 30 matrix has also been described as suitable for the in vitro culture of human chondrocytes (Delbruck et al, Conn. Tiss. Res. 15:155, 1986). Delbruck et al disclosed human chondrocytes distributed in the agarose and forming a pericellular region surrounded by an interterritorial-like
- 35 region. Type II collagen was detected in the gel matrix cultures by immunofluorescence and acid soluble collagens were examined by SDS polyacrylamide gel electrophoresis.

Watt and Dudhia (Differentiation 38:140, 1988)

- 5 -

disclose a composite gel of collagen and agarose for the culture of porcine chondrocytes. The composite gel prevented chondrocytes spreading. However, virtually no extracellular matrix was secreted in the low density culture composite gels.

Macklis et al (In Vitro Cell. Develop. Biol. 21:180, 1985) teach a collagen surface for culturing peripheral nervous system cells, comprising collagen derivatized to polystyrene plastic culture dishes.

10 Macklis et al disclose that the derivatized coating process yielded enhanced collagen adhesion and increased long term survival of cultured nerve cells, compared to collagen coating produced by absorption techniques.

SUMMARY OF THE INVENTION

15 The present inventor has reconstituted cartilage tissue on a substrate in vitro from isolated chondrocytes. The reconstituted cartilage tissue has a biochemical composition and cellular and matrix organization substantially the same as animal articular cartilage

20 tissue. In particular, the present inventor reconstituted cartilage characterized by a continuous layer of cartilage tissue having a substantial extracellular matrix and possessing zones very similar to those found in bovine cartilage in vivo. The superficial zone is characterized

25 by chondrocytes which are flattened and arranged parallel to the substrate, and a matrix which contains collagen fibres. Mid and deep zones have spherical chondrocytes and the matrix contains collagen fibres. The reconstituted cartilage tissue ultrastructurally has a

30 pericellular and interterritorial arrangement similar to that of in vivo bovine cartilage.

The reconstituted cartilage of the present invention also has a biochemical composition substantially the same as animal articular cartilage. In particular,

35 type II collagen is present throughout the reconstituted cartilage and the ratio of galactosamine to glucosamine amino sugars in the glycosaminoglycans in the reconstituted cartilage tissue of the invention is between

- 6 -

about 4.5 and 6.5. The reconstituted cartilage tissue of the invention under certain conditions also responds to interleukin 1 β in a similar manner to in vivo cartilage tissue.

5 Broadly stated the invention relates to cartilage tissue reconstituted in vitro having a biochemical composition and cellular and matrix organization substantially the same as animal articular cartilage tissue.

10 The invention also relates to a method for producing reconstituted cartilage tissue comprising isolating chondrocytes from articular cartilage tissue; forming a monolayer of chondrocytes on a substrate which is selected to permit growth media to be applied above and
15 below the substrate; culturing the chondrocytes on the substrate in growth media which is applied above and below the chondrocytes on the substrate, to produce a tissue having a biochemical composition and cellular and matrix organization substantially the same as articular cartilage
20 tissue.

 In one embodiment of the method of the invention, articular cartilage tissue is removed from the joint of an animal; the cartilage tissue is digested to obtain isolated chondrocytes; a monolayer of chondrocytes
25 is formed on a substrate which is selected to permit growth media to be applied above and below the substrate; the chondrocytes are cultured on the substrate in growth media which is applied above and below the chondrocytes on the substrate, to produce a tissue having a biochemical
30 composition and cellular and matrix organization substantially the same as articular cartilage tissue.

 The invention further relates to artificial cartilage tissue reconstituted in vitro by digesting cartilage tissue to obtain isolated chondrocytes; forming
35 a monolayer of chondrocytes on a substrate; culturing the chondrocytes and growth medium to produce a tissue having a biochemical composition and cellular and matrix organization substantially the same as articular cartilage

- 7 -

tissue.

The invention still further relates to a method of using the reconstituted cartilage tissue of the present invention to test pharmaceutical preparations for efficacy in the treatment of diseases of the joint and to a method of using the reconstituted tissue of the present invention as an implant to replace or repair damaged or deficient cartilage. The invention also relates to a method of treating a bone fracture by inserting the reconstituted tissue of the invention into the site of a bone fracture in a patient and to a method of testing for a substance that affects the growth of cartilage tissue comprising subjecting the tissue to a substance which is suspected of affecting the growth of cartilage tissue and determining the effect of the substance on the tissue.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a photomicrograph showing cartilage generated by chondrocytes cultured on collagen-coated inserts (F) and stained with Toluidine blue;

Figure 2 is a photomicrograph showing cartilage from the bovine joint;

Figure 3 is a photomicrograph of fetal cartilage showing the lack of cellular organization characteristic of articular cartilage (C);

Figure 4 is an electron micrograph of a chondrocyte surrounded by a pericellular matrix (→) and an interterritorial matrix within the cartilage tissue generated in culture on collagen-coated inserts;

Figure 5 is an electron micrograph of the interterritorial matrix of reconstituted cartilage tissue showing the presence of collagen fibers with characteristic periodic banding;

Figure 6 is a Western blot showing the presence of Type II collagen in a pepsin extract (E) of the cartilage tissue generated in culture and a collagen standard (S);

Figure 7 is a photomicrograph of a section of reconstituted cartilage tissue incubated with anti-Type II

- 8 -

collagen antibody, followed by anti-rabbit IgG conjugated to alkaline phosphatase;

Figure 8 is a photomicrograph of a section of reconstituted cartilage tissue incubated with antibody directed against Factor VIII related antigen and reacted as in Figure 7.

DETAILED DESCRIPTION OF THE INVENTION

As hereinbefore mentioned, the present invention provides cartilage tissue reconstituted in vitro having a biochemical composition and cellular and matrix organization substantially the same as animal articular cartilage tissue.

The reconstituted cartilage tissue of the invention is characterized by a continuous layer of cartilage tissue, having a substantial extracellular matrix, and comprising a superficial zone wherein the chondrocytes are flattened and arranged parallel to the substrate, and mid and deep zones wherein the chondrocytes are spherical and wherein the matrix in the superficial, mid and deep zones contains collagen fibers.

The present invention also relates to a method for producing reconstituted cartilage tissue. The method comprises isolating chondrocytes from articular tissue. In particular, articular cartilage may be removed from the joint of an animal and it may be digested to obtain isolated chondrocytes. A monolayer of chondrocytes is formed on a substrate and the chondrocytes are cultured in growth media to produce a tissue having a biochemical composition and cellular and matrix organization substantially the same as articular cartilage tissue.

The reconstituted cartilage tissue of the present invention may be prepared from chondrocytes isolated from articular cartilage from animals, preferably humans, bovines and rabbits, most preferably humans. A particularly useful system may be prepared from chondrocytes isolated from bovine articular cartilage, for example from the metacarpophalangeal joints. Chondrocytes that may be used in the method of the invention include

- 9 -

cells having a chondrocyte phenotype and progenitor cells of chondrocytes such as embryonal cells and mesenchymal cells.

The chondrocytes may be isolated using techniques known to those skilled in the art including sequential enzyme digestion techniques, such as those described in Kandel et al, Biochem. Biophys. Acta. 1035:130, 1990. For example, the cartilage may be treated with 0.5% protease followed by 0.04% bacterial collagenase.

The chondrocytes are plated on a substrate which is selected to permit growth media to be applied above and below the substrate. Preferably the substrate is a porous tissue culture insert, for example a Millicell®-CM insert, which has been coated with an attachment factor. Attachment factors are known in the art, see for example, Streuli and Bissell, J. Cell. Biol. 110:1405, 1990 and Buck and Horwitz, Ann, Rev. Cell Biol. 3:179, 1987. Examples of attachment factors include type I collagen, type II collagen, type IV collagen, a synthetic peptide of a segment of collagen, preferably a fifteen amino acid sequence ⁷⁶⁶GTPGPQGIAGQRGVV⁷⁸⁰ which is present in the $\alpha 1(1)$ chain of collagen (Bhatnagar and Qian, 38th Annual Meeting of the Orthopedic Research Society 17: 106, 1992), fibronectin, gelatin, laminin, polylysine, preferably poly-L-lysine and poly-D-lysine, vitronectin, cytotactin, echinonectin, entactin, tenascin, thrombospondin, uvomorulin, biglycan, chondroitin sulfate, decorin, dermatan sulfate, heparin, and hyaluronic acid. Preferably, the attachment factor used in the method of the invention is collagen, most preferably type I collagen. The chondrocytes are plated at a high cell density of at least 0.1 cm², preferably from 1.0 to 7x10⁶ cm².

In a preferred embodiment of the invention the substrate is a Millicell®-CM tissue culture insert, pore size 0.4 μ m, coated with a growth attachment factor, preferably collagen, most preferably type I collagen

- 10 -

diluted in acetic acid. The insert may subsequently be air dried and sterilized, for example by ultra violet light.

The chondrocytes seeded on the coated substrate, may be grown in suitable culture conditions. Examples of suitable culture media are known in the art, such as Ham's F12 medium. The culture medium may contain serum, for example fetal bovine serum in a concentration range of about 2-15% and may further contain growth factors and ascorbic acid. The culture media is applied above and below the substrate. The cells may be cultured at 37°C in a humidified atmosphere supplemented with CO₂, for at least 14 days. The cells may be cultured for less than 14 days to obtain a reconstituted product which does not entirely resemble cartilage tissue but which may be suitable for transplantation.

The present inventor has found that, after as little as 14 days in culture, the cells will produce a tissue with substantial extracellular matrix, which is substantially identical to in vivo bovine cartilage. The cells produce a substantial extracellular matrix and form a continuous layer of cartilage tissue possessing zones very similar to those found in natural bovine cartilage in vivo. The superficial zone is characterized by chondrocytes having a flattened morphology and a matrix which does not stain, or stains poorly, with toluidine blue, indicating the relative absence of sulphated proteoglycans. Chondrocytes in the mid and deep zones have a spherical appearance and the matrix contains abundant sulphated proteoglycans, as evidenced by staining with toluidine blue. Collagen fibers are present diffusely throughout the matrix.

The reconstituted cartilage tissue ultrastructurally has a pericellular and interterritorial arrangement similar to that of in vivo bovine cartilage. The chondrocytes possess abundant rough endoplasmic reticulum and are surrounded by matrix. The pericellular matrix contains numerous thin non-banded collagen fibers.

- 11 -

The collagen in the interterritorial matrix is less compacted and embedded in electron translucent amorphous material, similar to articular cartilage. Collagen fibers in the interterritorial region of the matrix exhibit the
5 periodic banding characteristic of collagen fibers in the interterritorial zone of cartilage tissue.

The biochemical composition of the reconstituted cartilage tissue is substantially the same as animal articular cartilage tissue. For example, the presence of
10 type II collagen in the reconstituted cartilage tissue is indicative of the differentiated phenotype of chondrocytes. The presence of type II collagen was determined in the reconstituted cartilage tissue by means of polyacrylamide gel electrophoresis and Western blot
15 analysis. Type II collagen is present throughout the reconstituted cartilage tissue as determined by immunohistochemical staining of the cartilage using polyclonal antibody directed against Type II collagen. The ratio of galactosamine to glucosamine amino sugars
20 found in the glycosaminoglycans present in cartilage in the reconstituted cartilage tissue of the present invention is between about 4.5 and 6.5.

The reconstituted cartilage tissue under certain conditions responds to interleukin 1β in a similar manner
25 to in vivo cartilage tissue. Interleukin 1β stimulates production of matrix metalloproteases that can degrade cartilage matrix macromolecules and inhibit synthesis of proteoglycans. Treatment of the reconstituted tissue with human recombinant interleukin 1β under certain conditions
30 results in a loss of cartilage and matrix components.

The reconstituted cartilage tissue of the present invention can be used as a model system for in vitro studies of cartilage structure, function and development. In particular, the reconstituted cartilage
35 tissue of the present invention may be used in the testing of pharmaceutical preparations useful in the treatment of diseases of the joint, for example osteoarthritis, inflammatory arthropathies, septic arthritis and

- 12 -

crystalline arthropathies. The reconstituted cartilage tissue of the invention may also be implanted into the joints of patients to replace or repair damaged or deficient cartilage. In addition the cartilage can be used to test angiogenic factors as the cartilage is normally resistant to vascular infiltration. It is also contemplated that the reconstituted cartilage tissue of the present invention can be used to enhance healing of bone fractures when inserted into the site of a fracture.

10 The reconstituted cartilage tissue of the invention may also be used to identify substances which affect the growth of cartilage tissue i.e. trophic factors. Thus, substances which inhibit or stimulate the growth of cartilage tissue may be identified by adding a substance suspected of affecting the growth of cartilage tissue to the reconstituted cartilage tissue of the invention and determining the effect of the substance. Agonists or antagonists of substances which stimulate or inhibit the growth of cartilage tissue may also be identified using the reconstituted tissue of the invention.

The following non-limiting examples are illustrative of the present invention:-

Example 1

25 Reconstituting Cartilage Tissue in Vitro

Chondrocytes were isolated from bovine articular cartilage obtained from metacarpophalangeal joints using the sequential enzyme digestion techniques described in Kandel et al, Biochem. Biophys. Acta. 1053:130 (1990). Briefly, the cartilage was treated with 0.5% protease for one hour and 0.04% bacterial collagenase overnight. The isolated chondrocytes were washed three times and plated at a cell density of approximately $1.5 \times 10^6/\text{cm}^2$ on collagen-coated Millicell®-CM porous tissue culture inserts.

To prepare the collagen-coated inserts, Millicell®-CM inserts, pore size 0.4 μm , were coated with Type I collagen (Vitrogen, Type I collagen, Collagen

- 13 -

Corporation), diluted to 1 mg/ml with 12 mM acetic acid. Following coating, the inserts were air dried for up to 18 hours and sterilized with ultraviolet light for 15 minutes.

5 The collagen-coated inserts, seeded with chondrocytes, were placed in sterile tissue culture wells and cultured in Ham's F12 medium, supplemented with 5% fetal bovine serum. The cells were cultured at 37°C in a humidified atmosphere supplemented with 5% CO₂. The medium
10 was changed 2.5 to 3 days after the initial plating and every 2 days thereafter. The volume of medium added depended on the size of inserts used. For the larger inserts (30 mm) 1.5 ml of medium was placed on top of the insert and 1.0 ml was placed underneath. The inserts were
15 harvested at selected time intervals up until 3 months, fixed and examined by light or electron microscopy.

For light microscopy, the inserts were fixed in 10% formalin, embedded in paraffin and cut into sections approximately 5 µm thick. The sections were stained with
20 either hematoxylin and eosin to visualize the cells or with the cationic dye, toluidine blue, to stain sulphated proteoglycans. In vivo samples of intact cartilage from bovine metacarpophalangeal joints were similarly processed for light microscopy.

25 For electron microscopy, representative portions of the insert culture were fixed in 2% glutaraldehyde for one hour at room temperature. The inserts were washed with phosphate buffer and then immersed in 1% osmium tetroxide for one hour at room temperature. The inserts
30 were washed with a phosphate buffer and dehydrated in graded ethanols to 100% ethanol. The inserts were immersed in 100% propylene oxide for 20 minutes, then embedded in plastic resin (Spurr®) and polymerized overnight at 70°C. Thin sections were cut and stained
35 with uranyl acetate and lead citrate before examination by electron microscopy.

After 2 weeks in culture the cells had produced a tissue with abundant extracellular matrix which was

- 14 -

substantially identical to bovine cartilage in vivo. Morphological comparisons were made between the cartilage tissue produced by in vitro culture, shown in Figure 1 and the in vivo cartilage tissue from the bovine joint, known
5 in the art, shown in Figure 2. Figure 2 shows the organization of chondrocytes in cartilage tissue dissected from the bovine joint. The chondrocytes in the superficial regions are flattened and the chondrocytes in the deep layers are more spherical. Toluidine blue
10 staining shows the presence of sulphated proteoglycans throughout the cartilage. The staining is lighter in the superficial zone suggesting there are fewer proteoglycans present. Fetal cartilage has no specific cellular organization as is shown in Figure 3.

15 The cartilage tissue grown in vitro, and shown in Figure 1, was found to closely resemble in vivo bovine articular cartilage. Examination of 4 week old cultures by light microscopy showed that the cells had produced abundant extracellular matrix and formed a continuous
20 layer of cartilage tissue possessing zones very similar to those found in natural bovine cartilage in vivo. The superficial zone was characterized by chondrocytes having a flattened morphology and a matrix which did not stain with toluidine blue, indicating the relative absence of
25 sulphated proteoglycans. Chondrocytes in the mid zone had a less flattened appearance and the matrix contained sulphated proteoglycans, as evidenced by the metachromasia produced by toluidine blue staining. Chondrocytes in the deep zone were spherical in appearance and the matrix was
30 metachromatic. Examination by polarized light microscopy showed the birefringence, indicative of collagen fibers.

Examination by electron microscopy showed that the cultured tissue had a pericellular and interterritorial arrangement similar to that of bovine
35 cartilage, as shown in Figure 4. Chondrocytes with abundant rough endoplasmic reticulum were observed surrounded by matrix. The pericellular matrix contained numerous thin nonbanded collagen fibers. The collagen in

- 15 -

the interterritorial matrix was less compacted and embedded in an electron translucent amorphous material similar to articular cartilage. Figure 5 shows collagen fibers from the interterritorial matrix of reconstituted cartilage tissue. The collagen fibers exhibit the periodic banding characteristic of collagen fibers in the interterritorial zone of in vivo cartilage tissue. Numerous electron dense granules were present, which appeared as dots throughout the matrix, indicating the presence of proteoglycans.

Example 2

In Vitro Synthesis of Type II Collagen

The presence of type II collagen in the cartilage tissue grown in vitro was measured to confirm that the cultured chondrocytes had maintained their differentiated phenotype.

Chondrocyte cultures were established, following the procedures outlined in Example 1 above, and maintained in culture for 2-4 weeks. The cartilage tissue was extracted with 100 µg/ml of pepsin at 4°C. After 24 hours an additional 100µg of pepsin was added and the extraction continued for another 24 hours. The pepsin extract was neutralized with the addition of an equal volume of Laemmli's buffer.

The presence of type II collagen was determined by polyacrylamide gel electrophoresis in the presence of sodium dodecylsulfate (SDS-PAGE) according to the procedure of Laemmli (U.K., Nature (London) 227, 680 (1974)). An 8% polyacrylamide gel was used. A sample of pepsin extract was applied to the gel and electrophoresed at 100 Ma for about 2 hours. Bands on the gel were visualized by staining with Coomassie Brilliant Blue. Only one band was observed co-migrating with the collagen standard. The identity of the band was confirmed by Western blot analysis to be type II collagen. The Western blot analysis was carried out by known standard techniques, generally as described in Coding, J.W., Monoclonal Antibodies: Principles and Practice, 2nd ed.,

- 16 -

Academic Press, London pp. 195-199, 1986. The band was transferred electrophoretically from the gel to nitrocellulose sheets and incubated with one of two antibodies directed against type II collagen or an antibody directed against type I collagen (Southern Biotechnology Assoc., U.S.A. One anti-type II collagen monoclonal antibody was obtained from Developmental Studies Hybridoma Bank, Iowa and one was a polyclonal antibody obtained from Southern Biotechnology Assoc. U.S.A. The blots were subjected to three washes and incubated for one hour in alkaline phosphatase conjugated to anti-IgG antibody. Blots were washed 3 times and developed with NBT/BCIP (Promega, U.S.A.) from 1 to 30 minutes, until colour developed.

Type II collagen was detected in the cultures as shown in Figure 6. Only type II collagen was detected in the pepsin extract of the reconstituted cartilage tissue, as indicated by the arrow on Figure 6. The results confirm that type II collagen is the major collagen produced by the chondrocyte culture.

The distribution of type II collagen in the chondrocyte cultures was examined as follows. Frozen sections of the cultured collagen tissue were predigested with 300 I.U. testicular hyaluronidase at 37°C for 15 minutes. The sections were washed in phosphate buffered saline and incubated with polyclonal anti-type II collagen antibody (Southern Biotechnology Associates 1:100 dilution), for 3 hours at room temperature. The sections were washed in phosphate buffered saline and then incubated for 45 minutes with anti-rabbit IgG antibody conjugated to alkaline phosphate (Vector, U.S.A.). The sections were washed three times. 5-Bromo-4-chloro-3-indolyl phosphate nitroblue tetrazolium was added for substrate, and colour development. The sections were then counterstained with nuclear fast red stain, coverslipped and examined by light microscopy. The blue staining indicates the presence of Type II collagen throughout the cartilage, as shown in Figure 7. Control sections were

- 17 -

stained with antibody directed against Factor VIII related antigen, which is not present in cartilage. The cartilage matrix was unstained in the control sections, as shown in Figure 8.

5

Example 3

Interleukin 1 Stimulates Matrix Loss in the Chondrocyte Culture.

Chondrocyte cultures were established as described above and grown for 2 weeks. The cultures were
10 incubated with 10 ng/ml of human recombinant interleukin 1 β (Ciba-Geigy, Switzerland) for seven days. After seven days the cultures were processed for light microscopy as described above in Example 1 and assessed histologically following staining with toluidine blue. Toluidine blue
15 staining was taken as an indication of the presence of sulphated proteoglycans. Toluidine blue staining was greatly diminished in cultures treated with IL-1, compared to untreated controls, indicating a loss of cartilage and matrix components in the remaining cartilage.

20

Example 4

Ratio of Galactosamine to Glucosamine

The ratio of galactosamine, which is present in chondroitin sulphate and dermatan sulphate, to glucosamine, which is present in hyaluronate and keratan
25 sulphate, was determined in the insert cultures and compared to the ratios in bovine articular cartilage.

The tissue sample, comprising bovine articular cartilage or cultured cartilage tissue following papain digestion was hydrolysed with 6 N hydrochloric acid and
30 examined by high pressure liquid chromatography using a Waters Pico Tag amino acid analysis system (Biotechnology Centre, University of Toronto) the ratio of galactosamine to glucosamine in the bovine articular cartilage was 5.55, whereas in the cultured cartilage, the ratio was 5.14.
35 There was no significant difference between the ratios, indicating that the ratio of these glycosaminoglycans are likely similar in both the intact tissue and the artificial tissue generated in culture. The ratio of

- 18 -

galactosamine to glucosamine is indicative of the types of glycosaminoglycans present in the extracellular matrix of the bovine cartilage and the cultured cartilage tissue.

- 19 -

I CLAIM:

1. Cartilage tissue reconstituted in vitro having
a biochemical composition and cellular and matrix
organization substantially the same as animal articular
5 cartilage tissue.
2. Cartilage tissue as claimed in claim 1 which is
further characterized by the presence of proteoglycans.
3. Cartilage tissue reconstituted in vitro having
a biochemical composition and cellular and matrix
10 organization substantially the same as animal articular
cartilage tissue and characterized by a continuous layer
of cartilage tissue, having a substantial extracellular
matrix and comprising:
a superficial zone wherein chondrocytes are
15 flattened and arranged parallel to the substrate;
mid and deep zones wherein the chondrocytes are
spherical;
and wherein the matrix in the superficial, mid
and deep zones contains collagen fibres.
- 20 4. Cartilage tissue as claimed in claim 3 which is
further characterized as follows: type II collagen is
present; galactosamine and glucosamine are present in a
ratio of between 4.5 and 6.5; and there is an increasing
abundance of sulphated proteoglycans from the superficial
25 to the mid and deep zones.
5. Cartilage tissue as claimed in claim 1 in
combination with a substrate.
6. Cartilage tissue as claimed in claim 5 wherein
the substrate comprises a porous tissue culture insert
30 coated with at least one attachment factor.
7. Cartilage tissue as claimed in claim 6 wherein

- 20 -

the porous tissue culture insert is a Millicell®-CM.

8. Cartilage tissue as claimed in claim 6 wherein at least one of the attachment factors is collagen.
9. Cartilage tissue as claimed in claim 8 wherein
5 the collagen is type I collagen.
10. A method for producing reconstituted cartilage tissue comprising:
isolating chondrocytes from articular cartilage tissue;
10 forming a monolayer of chondrocytes on a substrate which is selected to permit growth media to be applied above and below the substrate;
culturing the chondrocytes on the substrate in growth media which is applied above and below the
15 chondrocytes on the substrate, to produce a tissue having a biochemical composition and cellular and matrix organization substantially the same as articular cartilage tissue.
11. A method for producing reconstituted cartilage
20 tissue comprising:
removing articular cartilage tissue from an animal;
digesting said articular cartilage tissue to obtain isolated chondrocytes;
25 forming a monolayer of chondrocytes on a substrate which is selected to permit growth media to be applied above and below the substrate;
culturing the chondrocytes on the substrate in growth media which is applied above and below the
30 chondrocytes on the substrate, to produce a tissue having a biochemical composition and cellular and matrix organization substantially the same as articular cartilage tissue.

- 21 -

12. A method as claimed in claim 10 wherein the substrate is a porous tissue culture insert coated with at least one attachment factor.
13. A method as claimed in claim 11 wherein the substrate is a porous tissue culture insert coated with at least one attachment factor.
14. A method as claimed in claim 12 or 13 wherein the porous tissue culture insert is a Millicell®-CM.
15. A method as claimed in claim 12 or 13 wherein at least one of the attachment factors is collagen.
16. A method as claimed in claim 12 or 13 wherein at least one of the attachment factors is type I collagen.
17. A method as claimed in claim 10 or 11 wherein the chondrocytes are isolated from articular cartilage of humans.
18. A method as claimed in claim 10 or 11 wherein the chondrocytes are isolated from bovine articular cartilage.
19. A method as claimed in claim 10 or 11, wherein the chondrocytes are isolated by sequential enzyme digestion of the articular cartilage tissue.
20. A method as claimed in claim 10 or 11 wherein the isolated chondrocytes are embryonic or mesenchymal cells.
21. A method as claimed in claim 12 or 13 wherein the attachment factors are selected from the group consisting of type I collagen, type II collagen, type IV collagen, a synthetic peptide of a segment of collagen, fibronectin, gelatin, laminin, polylysine, vitronectin,

- 22 -

cytotactin, echinonectin, entactin, tenascin, thrombospondin, uvomorulin, biglycan, chondroitin sulfate, decorin, dermatan sulfate, heparin, and hyaluronic acid.

22. A method as claimed in claim 12 or 13, wherein
5 the chondrocytes are cultured at a cell density of at least 0.1 cm^2 .

23. A method as claimed in claim 12 or 13, wherein the chondrocytes are cultured at a cell density of 1.0 to $7 \times 10^6 \text{ cm}^2$.

10 24. A method as claimed in claim 10 or 11, wherein the growth media is Ham's F12 medium.

25. A method as claimed in claim 10 or 11, wherein the chondrocytes are cultured for at least 14 days.

26. A method as claimed in claim 10 or 11 which
15 further comprises implanting the tissue into a patient to replace or repair damaged or deficient cartilage.

27. A method as claimed in claim 10 or 11 which further comprises inserting the tissue into the site of a bone fracture in a patient to enhance healing of the bone
20 fracture.

28. A method as claimed in claim 10 or 11 which further comprises subjecting the tissue to a pharmaceutical preparation which is suspected of being useful in the treatment of diseases of the joint and
25 determining the effect of the pharmaceutical preparation on the tissue.

29. A method as claimed in claim 10 or 11 which further comprises subjecting the tissue to a substance which is suspected of effecting the growth of cartilage
30 tissue and determining the effect of the substance on the

- 23 -

tissue.

30. Cartilage tissue reconstituted in vitro by removing articular cartilage tissue from an animal; digesting said cartilage tissue to obtain isolated
5 chondrocytes; forming a monolayer of chondrocytes on a substrate; culturing the chondrocytes in growth media to produce a tissue having a biochemical composition and three dimensional organization substantially the same as articular cartilage tissue.



FIGURE 1

SUBSTITUTE SHEET




FIGURE 2 _

SUBSTITUTE SHEET




FIGURE 3



FIGURE 4

SUBSTITUTE SHEET




FIGURE 5


SUBSTITUTE SHEET

Type I

Type II



S E



S E

FIGURE 6

SUBSTITUTE SHEET



FIGURE 7
SUBSTITUTE SHEET




FIGURE 8

INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 93/00111

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC		
Int.Cl. 5 C12N5/06; C12Q1/18	C12N5/08;	A61K35/32; A61L27/00
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
Int.Cl. 5	C12N ; A61K ; A61L ; C12Q	
Documentation Searched other than Minimum Documentation to the extent that such Documents are included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹		
Category *	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
X	CLINICAL ORTHOPAEDICS AND RELATED RESEARCH vol. 186, June 1984, PHILADELPHIA, PA, US pages 231 - 239 T. KIMURA ET AL. 'CHONDROCYTES EMBEDDED IN COLLAGEN GELS MAINTAIN CARTILAGE PHENOTYPE DURING LONG-TERM CULTURES.'	1-4
Y	see the whole document	5-30
Y	EP,A,0 396 138 (MILLIPORE CORPORATION) 7 November 1990 see page 2, column 2, line 17 - line 20; claims 1-3,11; examples 1,2 see page 3, column 3, line 1 - line 14 see page 3, column 3, line 31 - line 39	5-30
	-/--	
<p>⁶ Special categories of cited documents: ¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
01 JULY 1993	14-07-1993	
International Searching Authority	Signature of Authorized Officer	
EUROPEAN PATENT OFFICE	RYCKEBOSCH A.O.	

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category*	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
X	EP,A,0 175 286 (MCW RESEARCH FOUNDATION, INC.) 26 March 1986 see page 4, line 27 - page 5, line 10; examples 1-3 see page 30, line 28 - page 31, line 26 -----	1-5,10, 11, 17-20, 24-30
X	WO,A,9 012 603 (J.P. VACANTI ET AL.) 1 November 1990 see page 9, line 26 - line 36; claims see page 12, line 3 - line 25; example 2 -----	1-6,8, 10-13, 15,17-30

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

CA 9300111
SA 72362

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
The numbers are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

01/07/93

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0396138	07-11-90	US-A- 4996154	26-02-91
		JP-A- 3164168	16-07-91
		US-A- 5175092	29-12-92
EP-A-0175286	26-03-86	US-A- 4757017	12-07-88
		CA-A- 1247542	27-12-88
		JP-A- 61108386	27-05-86
WO-A-9012603	01-11-90	US-A- 5041138	20-08-91
		AU-B- 635025	11-03-93
		AU-A- 5556890	16-11-90
		CA-A- 2051663	18-10-90
		EP-A- 0469070	05-02-92
		JP-T- 4505717	08-10-92

EPO FORM P007

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82